This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.
Clinical evaluation of new vaccines - Scientific guideline
Human medicines European public assessment report (EPAR): Voydeya, Danicopan, Da...
Human medicines European public assessment report (EPAR): Evkeeza, evinacumab, D...
Meeting of the Medicine Shortages Single Point of Contact (SPOC) Working Party, ...
Human medicines European public assessment report (EPAR): Biktarvy, bictegravir,...
Human medicines European public assessment report (EPAR): Fasenra, benralizumab,...
Human medicines European public assessment report (EPAR): Somavert, pegvisomant,...
Herbal medicinal product: Pilosellae herba cum radice, Hieracium pilosella L., F...
Herbal medicinal product: Tribuli terrestris herba, Tribulus terrestris L., D: D...
Herbal medicinal product: Prunus avium peduncle, Prunus avium L.,Prunus cerasus ...
Human medicines European public assessment report (EPAR): Wezenla, ustekinumab, ...
Human medicines European public assessment report (EPAR): Steqeyma, ustekinumab,...
Annex - National provisions for SMEs applicable to the pharmaceutical sector
Certificates Processing System: Demo & Q&A session for industry stakeholders, On...
Human medicines European public assessment report (EPAR): Kostaive, zapomeran, S...
Human medicines European public assessment report (EPAR): Micardis, telmisartan,...
Joint EC/HMA/EMA multi-stakeholder workshop on pharmacogenomics, Online, Europea...
Human medicines European public assessment report (EPAR): Fampridine Accord, fam...
Human medicines European public assessment report (EPAR): MicardisPlus, Date of ...
Human medicines European public assessment report (EPAR): Herzuma, trastuzumab, ...
Human medicines European public assessment report (EPAR): GeGant, Germanium (68G...
Human medicines European public assessment report (EPAR): ProQuad, measles, mump...
Human medicines European public assessment report (EPAR): Aripiprazole Accord, a...
Human medicines European public assessment report (EPAR): Sunlenca, lenacapavir,...